Mexican researchers highlight a novel approach to discovering drugs for Chagas disease in a laboratory study reported in PLoS Neglected Tropical Diseases.

Chagas disease, caused by the parasite Trypanosoma cruzi, affects about 18 million people in the American continent. Unfortunately, there is no satisfactory treatment for the disease: the existing drugs have severe side effects, require long courses of treatment, and show variable effectiveness.

In the new study, Armando Gómez-Puyou (Universidad Nacional Autonoma de Mexico, Mexico City) and colleagues report results of their search for molecules that could eliminate the parasite. Their work targets an enzyme in the parasite called triosephosphate isomerase.

One of the problems with identifying molecules that attack parasitic enzymes is that most of these enzymes have a counterpart in the human host-and so the molecule may also attack the human enzyme (causing side effects in humans). But triosephosphate isomerase, which has two subunits, holds promise as a possible target because the human form differs from the parasitic form. Armando Gómez-Puyou and colleagues found significance differences in the interface between the two subunits in triosephosphate isomerase from Homo sapiens and that from Trypanosoma cruzi. They therefore searched for molecules that could specifically disrupt this interface in the parasitic form of the enzyme but not the human form.

In their search, they discovered that dithiodianiline (DTDA) is far more effective at inactivating the parasitic form of the enzyme than the human form, and its detrimental effect is due to it perturbing the interface between the two subunits.

By targeting this interface, the researchers say, "it is possible to discover small molecules that selectively thwart the life of the   parasite."

Citation: Olivares-Illana V, Rodríguez-Romero A, Becker I, Berzunza M, García J, et al. (2007) Perturbation of the Dimer Interface of Triosephosphate Isomerase and its Effect on Trypanosoma cruzi. PLoS Negl Trop Dis 1(1): e01. doi:10.1371/journal.pntd.0000001
Please click here

Disclaimer

This press release refers to upcoming articles in PLoS Neglected Tropical Diseases. The release is provided by journal staff. Any opinions expressed in these releases or articles are the personal views of the journal staff and/or article contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

About PLoS Neglected Tropical Diseases

PLoS Neglected Tropical Diseases is the first open-access journal devoted to the world's most neglected tropical diseases (NTDs), such as elephantiasis, river blindness, leprosy, hookworm, schistosomiasis, and African sleeping sickness. The journal will publish high-quality, peer-reviewed research on all scientific, medical, and public-health aspects of these forgotten diseases affecting the world's forgotten people. For more information, visit plosntds.

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource.

Public Library of Science
185 Berry Street, Suite 3100
San Francisco, CA 94107
USA

Tag Cloud